MedTrace Logo

A Study of Danning Tablet in Patients With Polypoid Lesions of Gallbladder

NCT05668871 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2026-08-05

No results posted yet for this study

Summary

The primary aim of this study is to evaluate the efficacy and safety of Danning Tablets in the treatment of MGPs. Specifically, the study seeks to determine whether Danning Tablets, when used alongside standard care, can effectively reduce the size of MGPs and improve related symptoms.

Conditions

  • Multiple Gallbladder Polyps

Interventions

DRUG

Danning Tablet

5 tablets per time, 3 times daily, taken orally after meals

BEHAVIORAL

Lifestyle Management

Lifestyle intervention includes dietary advice to avoid cold, spicy, sour, and other irritating foods,abstain from smoking and alcohol, and to avoid excessive fatigue and emotional stress. Aregular, low-fat, low-calorie diet is recommended, along with a consistent and timely eatingschedule.

Sponsors & Collaborators

  • Eastern Hepatobiliary Surgery Hospital

    lead OTHER

Principal Investigators

  • Feng Shen, MD, PhD · Eastern Hepatobiliary Surgery Hospital, Naval Medical University

  • Tian Yang, MD, PhD · Eastern Hepatobiliary Surgery Hospital, Naval Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2026-02-25
Completion
2026-02-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05668871 on ClinicalTrials.gov